Provided by Tiger Trade Technology Pte. Ltd.

MannKind

3.79
-0.1500-3.81%
Post-market: 3.790.00000.00%16:10 EDT
Volume:3.21M
Turnover:12.22M
Market Cap:1.22B
PE:-27.07
High:3.90
Open:3.90
Low:3.76
Close:3.94
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:0.90
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-18.14
PE(LYR):189.50

Loading ...

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

GlobeNewswire
·
May 30

MannKind Shares Rise 6.4% After US FDA Approves Co's Inhaled Insulin for Children

THOMSON REUTERS
·
May 30

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

TIPRANKS
·
May 30

BRIEF-Mannkind Says Afrezza Available To Eligible Patients For $35 Or Less Per Month

Reuters
·
May 30

MannKind says FDA approves Afrezza inhaled mealtime insulin for children aged 6 and older

Reuters
·
May 30

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living With Diabetes

THOMSON REUTERS
·
May 30

MannKind - Afrezza Available to Eligible Patients for $35 or Less per Month

THOMSON REUTERS
·
May 30

Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)

TIPRANKS
·
May 28

MannKind Released From Major Afrezza Trial Obligation

TIPRANKS
·
May 28

BRIEF-Mannkind Says FDA Releases Company From Postmarketing Requirement For Afrezza On May 27 - SEC Filing

Reuters
·
May 28

MannKind - FDA Releases MannKind From Postmarketing Requirement for Afrezza on May 27, 2026 - SEC Filing

THOMSON REUTERS
·
May 28

FDA lifts MannKind postmarketing study requirement for Afrezza pulmonary cancer risk

Reuters
·
May 28

MannKind CEO Castagna joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

MannKind presents new Afrezza pediatric efficacy data from INHALE-1 study at ADA 2026

Reuters
·
May 27

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

GlobeNewswire
·
May 27

MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles

TIPRANKS
·
May 23

MannKind shareholders elect nine directors at annual meeting

Reuters
·
May 23

MannKind EVP, General Counsel David Thomson disposes 15,420 shares worth $53,624.52

Reuters
·
May 14

MannKind director Steven B. Binder disposes of 22,500 shares worth $75,927.40

Reuters
·
May 14

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08